Skip to content

B-cell levels and breastmilk transfer in infants of lactating women with multiple sclerosis treated with ocrelizumab: Primary results of the prospective, multicentre, open-label, phase IV study SOPRANINO

In women with multiple sclerosis, relapse risk increases in the postpartum period; however, both breastfeeding and the use of disease-modifying therapy can decrease this risk. Here we present the primary analysis from the SOPRANINO study (NCT04998851), the first prospective study to measure B-cell levels in breastfed infants in addition to pharmacokinetic parameters of ocrelizumab in breastmilk.

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

Send Via Email

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.

Leave Site Stay on Medically